|
|
|
|
|
|
|
||
Article |
Evidence from the Analysis of Disease-linked Mutations
Corresponding author: Robert S. Kass, Department of Pharmacology, College of Physicians and Surgeons of Columbia University, 630 W. 168th St. New York, NY 10032. Fax: 212-342-2703; E-mail: rsk20{at}columbia.edu
Na+ channel blockers such as flecainide have found renewed usefulness in the diagnosis and treatment of two clinical syndromes arising from inherited mutations in SCN5A, the gene encoding the 
subunit of the cardiac voltage–gated Na+ channel. The Brugada syndrome (BrS) and the LQT-3 variant of the Long QT syndrome are caused by disease-linked SCN5A mutations that act to change functional and pharmacological properties of the channel. Here we have explored a set of SCN5A mutations linked both to BrS and LQT-3 to determine what disease-modified channel properties underlie distinct responses to the Na+ channel blocker flecainide. We focused on flecainide block that develops with repetitive channel activity, so-called use-dependent block (UDB). Our results indicate that mutation-induced changes in the voltage-dependence of channel availability (inactivation) may act as determinants of flecainide block. The data further indicate that UDB by flecainide requires channel opening, but is not likely due to open channel block. Rather, flecainide appears to interact with inactivation states that follow depolarization-induced channel opening, and mutation-induced changes in channel inactivation will alter flecainide block independent of the disease to which the mutation is linked. Analysis of flecainide block of mutant channels linked to these rare disorders has provided novel insight into the molecular determinants of drug action.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Nilsson, M. Madeja, F. Elinder, and P. Arhem Bupivacaine Blocks N-Type Inactivating Kv Channels in the Open State: No Allosteric Effect on Inactivation Kinetics Biophys. J., December 1, 2008; 95(11): 5138 - 5152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Stokoe, G. Thomas, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/{Delta} murine hearts modelling long QT syndrome 3 J. Physiol., January 1, 2007; 578(1): 69 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vecchietti, E. Grandi, S. Severi, I. Rivolta, C. Napolitano, S. G. Priori, and S. Cavalcanti In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H56 - H65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Clancy, Z. I. Zhu, and Y. Rudy Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H66 - H75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, J. W. Kyle, and P. J. Lee Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H29 - H37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Nerbonne and R. S. Kass Molecular Physiology of Cardiac Repolarization Physiol Rev, October 1, 2005; 85(4): 1205 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Clancy and R. S. Kass Inherited and Acquired Vulnerability to Ventricular Arrhythmias: Cardiac Na+ and K+ Channels Physiol Rev, January 1, 2005; 85(1): 33 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Bechtold, X. Yue, R. M. Evans, M. Davies, N. A. Gregson, and K. J. Smith Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide Brain, January 1, 2005; 128(1): 18 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ramos and M. E O'Leary State-dependent trapping of flecainide in the cardiac sodium channel J. Physiol., October 1, 2004; 560(1): 37 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tateyama, H. Liu, A-S. Yang, J. W. Cormier, and R. S. Kass Structural Effects of an LQT-3 Mutation on Heart Na+ Channel Gating Biophys. J., March 1, 2004; 86(3): 1843 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Motoike, H. Liu, I. W. Glaaser, A.-S. Yang, M. Tateyama, and R. S. Kass The Na+ Channel Inactivation Gate Is a Molecular Complex: A Novel Role of the COOH-terminal Domain J. Gen. Physiol., January 26, 2004; 123(2): 155 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Desaphy, A. D. E. Luca, M. P. Didonna, A. L. George Jr, and D. C. Camerino Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block J. Physiol., January 15, 2004; 554(2): 321 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Wang, C. Russell, and S.-Y. Wang State-dependent Block of Wild-type and Inactivation-deficient Na+ Channels by Flecainide J. Gen. Physiol., August 25, 2003; 122(3): 365 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, J. Atkins, and R. S. Kass Common Molecular Determinants of Flecainide and Lidocaine Block of Heart Na+ Channels: Evidence from Experiments with Neutral and Quaternary Flecainide Analogues J. Gen. Physiol., February 24, 2003; 121(3): 199 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
